A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

European drug regulators classify NAION as a 'very rare' side effect of semaglutide — the active ingredient in Ozempic, Wegovy. The risk often emerged after two years of use ...

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

WEIGHT loss jabs are weaving themselves into the fabric of our daily lives and chances are you know someone taking them – or ...

The popularity of weight-loss jabs such as Ozempic and Wegovy has exploded in the last couple of years. The drugs, both ​​semaglutides, stimulate GLP-1 receptors in the brain. They mimic the sensation ...